IO Biotech said on Monday its experimental combination vaccine for a type of skin cancer helped slow the disease's ...

Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.

Merck MRK announced mixed second-quarter results last month. The company beat estimates for earnings while meeting the same ...

IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...

The system for compensating people injured by vaccines needs significant reform. But the health secretary could alter it in ...

IO Biotech said on Monday its experimental cancer vaccine, in combination with Merck's Keytruda, showed improvement in a late ...

Arcus Biosciences nears key catalysts with late-stage assets & upcoming Phase 3 data. Discover potential upside & why it's ...

These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A Newsweek report reveals America's Most Responsible Companies for 2025, with a New Jersey-based company earning the top spot ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Since its inception, Merck Foundation has provided 63 scholarships to Nigerian doctors, enabling them to specialise in 42 ...